The SVR10K Hepatitis C study: final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordics, and Southern Europe

Background and Aims: A previously published real-world data analysis demonstrated high effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in>6,000 HCV patients from 12 clinical cohorts across Australia, Canada, Europe & USA. Irrespective of age, male patients were more likely to have advanced fibrosis and infection with HCV GT 3, and median time to treatment initiation was numerically shorter in male patients across the age spectrum. The aim of this large real-world analysis was to evaluate characteristics and outcomes in an expanded pool of HCV patients treated with SOF/VEL across regions globally.